Navigation Links
Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
Date:9/18/2007

INDIANAPOLIS, Sept. 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Robert J. Heine, M.D., Ph.D., F.R.C.P., will join Lilly in January, 2008, as Executive Medical Director for the Diabetes and Endocrine division responsible for development of Lilly's expanding diabetes and obesity R&D portfolio. Dr. Heine replaces Dr. Meng Hee Tan, Distinguished Medical Fellow, Diabetes and Endocrine, who will retire at the end of September after 8 years of outstanding service to the company.

"Lilly has a growing and exciting diabetes and obesity R&D portfolio that demands exceptional clinical leadership to guide and successfully develop," said Vince Mihalik, Vice President and Global Brand Development Platform Leader, Diabetes, Obesity and Endocrine. "Robert is widely recognized and respected in the diabetes community for his scientific and clinical excellence and his considerable leadership abilities. He'll be a fantastic addition to the Lilly team."

Heine is currently professor of diabetology in the Department of Endocrinology and director of the Diabetes Centre at the VU (Vrije Universiteit) University Medical Center in Amsterdam, Netherlands. In addition to involvement in several research projects, Heine holds positions within the European Association for the Study of Diabetes (EASD), the European Foundation for the Study of Diabetes (EFSD) and the American Diabetes Association (ADA), including chair of the EASD subcommittee for Clinical Research Training, president of the organizing committee for the 2007 EASD annual meeting, and a member of the ADA Expert Committee on guidelines for the treatment of hyperglycemia in type 2 diabetes. He is a prolific author, with more than 350 published papers, and currently serves as associate editor of Diabetic Medicine and an editorial board member for several other publications. Heine's primary research interests include the epidemiology and pathophysiology of type 2 diabetes.

"We couldn't be more pleased that Dr. Heine has decided to bring his considerable talents to Lilly," said David Moller, M.D., Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories. "Robert's outstanding clinical experience and depth of scientific expertise will be a major contributor to the sustained leadership of Lilly in diabetes and related metabolic disorders as we continue to bring novel medicines to patients in need around the world."

"It's a privilege to join a team with such an impressive history of innovation and one that is also shaping the future of diabetes care," said Heine. "I'm excited for the opportunity to work in a new and dynamic atmosphere at Lilly with a group of truly talented scientists."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Crohns Patient Robert Hill’s greatest achievemen
2. Relapse in Risk Management System Claims the Life of Robertson
3. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
4. Distinguished Scientist Award Conferred on Manchester Dentist
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Is Diabetes the Leading Cause of Kidney Failure in India
7. Diabetes and Depression often go hand-in-hand
8. Vitamin E, the latest warrior against diabetes
9. Thirty minutes of work up per day reduces the risk of Diabetes
10. New Drug for Diabetes
11. Diabetes, obesity rates shooting up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology: